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Abstract
The European Network for Breast Development and
Cancer (ENBDC), a worldwide network (http://www.
enbdc.org/), celebrated its tenth anniversary with a
fantastic meeting last March 15–17, 2018 in Weggis
with 76 attendees.
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During the past 10 years European scientists working on
breast development and cancer have met yearly in
Weggis to share their knowledge on novel technologies
and procedures as well as the most recent scientific
achievements in the field. The European Network of
Breast Development and Cancer (ENBDC) community
has been growing steadily, with members from 13 differ-
ent European countries, as well as non-European mem-
bers and attendees of the ENBDC yearly workshop.
The chair of this year’s meeting, Eva Gonzalez Suarez
(PEBC, IDIBELL, Barcelona, Spain), together with the
PhD/postdoc chairs, Karsten Bach (University of Cam-
bridge, UK) and Johanna Englund (University of
Helsinki, Finland) have put together an amazing pro-
gram. The meeting was organized in four lecture ses-
sions with a total of nine speakers, opening and closing
keynote sessions, and six short talks selected from the
abstracts. Two poster sessions, with a total of 47 posters,
allowed an active role for every attendee.
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In this tenth anniversary one of our goals was to en-
courage young scientists to pursue their careers in sci-
ence and maintain research excellence in mammary
gland biology and breast cancer in Europe and world-
wide. Towards this aim we invited as a keynote speaker
Zena Werb (University of California San Francisco,
USA), whose revolutionary work in the mammary gland
and breast cancer field has been inspirational for many
scientists worldwide. Zena Werb and the rest of the
speakers have contributed to mentoring, motivating, and
inspiring the next generation of scientists.
Zena Werb discussed her recent findings using single
cell RNAseq analyses of human mammary epithelial
cells [1]. This technology allows the reconstitution of
differentiation trajectories, clarifying the developmental
hierarchy of mammary subpopulations. Her data reveal
the existence of multiple basal and luminal human
mammary subpopulations, highlighting a heterogeneity
that is starting to be appreciated. These results nicely
complement similar studies performed on the mouse
mammary gland [2, 3]. Single cell gene expression ana-
lyses in metastatic cells from tissues with low and high
metastatic burden revealed how early stage metastatic
cells possess a distinct stem-like gene expression signa-
ture. By contrast, metastatic cells from high burden
metastatic sites were similar to primary tumors [4].
Phylogenic lineage analyses and pseudotime ordering re-
vealed that low burden metastatic cells exit dormancy
and enter the cell cycle upon upregulation of c-MYC.
These c-MYC-positive cells can be killed with the CDK
inhibitor dinaciclib. She finished her presentation by de-
scribing cancer as a systemic disease, as revealed by the
expansion of neutrophils in peripheral tissues prior to
metastasis detection, and showing that metastasis can be
reduced by blockage of G-CSF [5, 6].
The first session, on Biomechanics and Imaging,
brought insights into the fundamental mechanisms of
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cell mechanosensing and mammary gland development.
Mechanical properties of extracellular matrix (ECM)
regulate normal mammary gland development and
pathological processes, including breast cancer progres-
sion [7]. Therefore, it is of high interest to understand
how the cells detect, transmit, and respond to mechan-
ical signals (mechanosensing and mechanosignaling).
Pere Roca-Cusachs (IBEC, Barcelona, Spain) introduced
the model of a dynamic molecular clutch of actin–talin–
integrin–fibronectin, which explains how matrix rigidity
and density results in force transmission and transduc-
tion. His team identified talin unfolding as the critical
mechanism that triggers force transduction. Above a
stiffness threshold talin unfolds and binds to vinculin,
leading to adhesion growth and nuclear translocation of
YAP [8], a mechanosensitive transcriptional regulator
with critical roles in development, regeneration, and
cancer. Furthermore, Roca-Cusachs’ team demonstrated
that YAP nuclear translocation can be driven directly by
force applied to the nucleus [9]. Force transmission from
the cytoskeleton to the nucleus leads to nuclear flatten-
ing, which reduces mechanical restriction in nuclear
pores and increases YAP nuclear import. Importantly,
their findings revealed a novel mechanosensing mechan-
ism directly converting force into nuclear molecular im-
port that may play a central role in transcriptional
regulation in response to mechanical cues. Future work
should resolve how mechanosensing is regulated in com-
plex, three-dimensional (3D) multi-cellular environ-
ments such as the mammary gland.
Colinda Scheele from Jacco van Rheenen laboratory
(Netherlands Cancer Institute, Amsterdam, Netherlands)
caught the attention of the ENBDC attendees with im-
pressive intravital two-photon microscopy videos and
images of mouse mammary glands and talked about the
mechanism of mammary branching morphogenesis dur-
ing puberty. They and their collaborators from the la-
boratory of Benjamin D. Simons (University of
Cambridge, UK) used whole-mount analysis of mam-
mary epithelial branching patterns, large-scale mammary
gland reconstructions, proliferation kinetics measure-
ments, and mathematical modeling to clarify the rules of
mammary branched network topology and spatial pat-
terning formation. Their results showed that all mam-
mary trees follow three universal branching rules: ductal
elongation only takes places in the terminal end bud
(TEB), bifurcation only happens in the TEB, and a
branch is terminated if it comes closer to another
branch [10, 11]. Moreover, they found that these rules
(that ductal tips grow and branch as a default state and
stop dividing in high-density regions) also apply to pat-
tern formation in other branched organs, including kid-
ney and prostate [10, 11]. Intriguingly, despite evidence
on side branching from other studies, they did not
observe any side branching during pubertal mammary
gland development in their intravital imaging work, nor
did their mathematical modeling provide support for
such a mechanism. Future work needs to clarify this
discrepancy.
The second session, on Mechanisms of Mammary
Tumorigenesis, started with a talk by Marie Ange Deugnier
(Institut Curie, Paris, France) in which she presented their
findings on the role of podoplanin (Pdpn) in mammary
gland development and tumorigenesis. They identified
PDPN as a specific marker of basal cells, including multipo-
tent stem cells, that positively regulates the Wnt/β-catenin
signaling pathway [12]. P-ERM, RhoGTPases, and changes
in the cytoskeleton actin fibers could mediate these effects.
Moreover, loss of Pdpn attenuated tumorigenesis in a
mouse model of β-catenin-induced breast cancer by limit-
ing tumor-initiating cell expansion. Taken together, their
work defines Pdpn as a regulator of mammary stem cell
function and tumorigenesis by potentiating Wnt/β-catenin
signaling [12]. Future work should evaluate the clinical im-
portance of Pdpn and its possible use as a marker for pro-
gression from in situ to invasive breast cancer.
Tumor recurrence is the leading cause of breast
cancer-related death. Recurrences arise from residual can-
cer cells which survive initial therapeutic intervention.
The characteristics of these cells, also referred to as min-
imal residual disease (MRD), have been elusive due to dif-
ficulties in obtaining clinical samples of MRD. To shed
some light on MRD, the group of Martin Jechlinger
(EMBL, Heidelberg and Monterotondo) employed mouse
models and organoid culture models to mimic residual
disease and recurrence. In these models tissue-specific in-
duction of oncogene expression (Myc/Neu or Myc/
KrasG12D) results in invasive carcinomas (or their 3D cul-
ture equivalent, large acini with filled lumen). Following
oncogene inactivation, the tumors completely regress to a
non-palpable state (polarized acini in 3D culture) and,
with time, spontaneous tumor recurrences develop. Using
these models Martin Jechlinger’s group discovered that re-
sidual cells acquire a transcriptionally distinct state from
normal epithelium and primary tumors, which results in
altered lipid metabolism and elevated reactive oxygen spe-
cies (ROS) [13]. Subsequently, increased oxidative DNA
damage potentiates the acquisition of somatic mutations
during hormonal-induced expansion of the mammary cell
population and leads to tumor recurrence [13]. Import-
antly, these newly discovered characteristics were also de-
tected in residual cancer cells from neoadjuvant-treated
breast cancer patients and provide an opportunity for
therapeutic intervention. As Martin Jechlinger showed, re-
duction of ROS levels and proliferation of mammary epi-
thelium attenuated recurrence in vitro and in vivo [13].
Jeff Pollard (MRC Centre for Reproductive Health,
Edinburgh, UK) opened the Tumor Immunology session
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discussing the effect of the tumor microenvironment in
tumor progression. Although it has been established that
the tumor microenvironment can suppress tumor phe-
notypes, a large body of work produced from Pollard’s
laboratory and many others have clearly demonstrated
that macrophages can promote tumor progression and
metastasis [14]. Studies into the mechanisms behind
pro-tumoral effects of macrophages on metastatic dis-
ease in breast cancer show that macrophages promote
tumor cell extravasation, survival, and persistent growth
in the lung. Several macrophage-tumor cell-signaling
pathways that result in the enhancement of metastasis
were highlighted, including the ligands CCL2, VEGF, and
CSF-1 and their respective receptors [15]. Recruited
macrophages were examined via imaging windows in the
lung that allow visualization of extravasation using mul-
tiphoton imaging [16]. Cancer cells modify their protru-
sion activity prior to extravasation and appear to attach
to collagen fibers during the process of egress from the
lung capillaries. Tracking the fate of recruited classic
monocytes, novel immune suppressive precursors of
metastasis-associated macrophages were described in the
tissue [17]. These immunosuppressive cells suppress the
cytotoxicity of activated CD8+ cells partially through
superoxide production and can be targeted to prevent
breast cancer metastasis. Signals derived from
metastasis-associated macrophages determine the meta-
static ability of cancer cells. In a recent work from Pol-
lard’s laboratory he has also shown the fate of recruited
monocytes in primary tumors which uni-directionally
transit through to perivascular macrophages that promote
tumor cell intravasation [5]. Knowledge of these mecha-
nisms of monocyte recruitment, retention, and differenti-
ation to mature macrophages that promote tumor
progression could lead to therapeutic opportunities to in-
hibit metastasis that kills most cancer patients.
Cellular surveillance (apoptosis, senescence) and im-
mune surveillance (cytotoxicity) protect us from cancer.
Tumor cells feature a plethora of different mechanisms
to escape immune surveillance, including loss of MHC1
expression, secretion of the immunosuppressive cytokine
TGFβ, and recruitment of immunosuppressive cells:
myeloid derived suppressor cells and T regulatory cells
(Tregs) [18]. Christophe Caux (Centre Leon Berard,
Lyon, France) spoke about mechanisms of
Treg-mediated suppression in breast tumors and target-
ing of the tumor and its immune environment [19].
Caux reported that Treg infiltrating (Ti-Treg) breast
cancers have a negative impact on patient outcome.
Ti-Tregs are selectively recruited into the tumor envir-
onment through CCL22 secretion and expand after
ICOS engagement by dendritic cells. Ti-Tregs express
high levels of CD39, an ectonucleotidase that cooperates
with CD73 to degrade ATP into immunosuppressive
adenosine (Ado), which inhibits most inflammatory cyto-
kines except IL-17A. CD73 defines a subset of effector
CD4+ T cells (Teffs). CD39+ Tregs selectively target
CD73+ Teffs through cooperative degradation of ATP into
Ado, which inhibits and restricts the ability of CD73+
Teffs to secrete IL-17A. CD73+ Teffs that infiltrate breast
tumors are inactivated by Tregs expressing high levels of
CD39 and ATPase activity. Tumor-infiltrating CD73+
Teffs fail to express inhibitory immune checkpoints, sug-
gesting that CD73 might be selected under pressure from
immune checkpoint blockade therapy and could represent
a target for restoring anti-tumor immunity based on the
reactivation of immune surveillance [19].
Emerging evidence indicates that neutrophils’ diverse
phenotypic and functional polarization states are able to
alter tumor behavior. Cancer patients with high neutro-
phil to lymphocyte ratios in circulation are at increased
risk of developing recurrence disease years later [20] .
The work of Karin de Visser (Netherlands Cancer Insti-
tute, Amsterdam, Netherlands) demonstrated that tu-
mors induce systemic neutrophil expansion and
polarization by stimulating a CCL2/IL-1β/IL-17/G-CSF
cascade that involves macrophages and gamma-delta T
cells [21, 22]. Neutrophil depletion drastically impairs
lymph node and lung metastasis without impacting pri-
mary tumor growth. Next, Karin presented a compre-
hensive study of 16 genetically engineered mouse (GEM)
tumor models developed by her collaborator, Jos Jonkers
(NKI, Amsterdam), in which hallmarks of systemic in-
flammation during tumorigenesis were assessed. The
p53 status of mammary tumors strongly correlates with
neutrophil abundance. Mice with p53-deficient tumors
exhibit extensive neutrophil expansion while those with
tumors with functional p53 show only moderate neutro-
phil expansion. Neutrophil accumulation in mice bearing
p53-deficient mammary tumors was associated with ele-
vated IL-1β, IL-17, G-CSF, and CCL2 levels in serum.
Macrophages grown in conditioned medium from tumor
cells with p53 deletions are induced to secrete IL-1β, a
potent inflammatory cytokine, suggesting macrophages
are altered by the p53 mutant secretome. Analysis of the
unique panel of GEM models using RNAseq data leads
to clustering based on their p53 status. A number of se-
creted factors are up-regulated in p53-deficient tumors
and cell lines and studies are ongoing to dissect which
of these mediators may drive the pro-metastatic systemic
neutrophilic inflammation in hosts bearing p53-deficient
mammary tumors. The IL-1β/neutrophil axis represents
an exciting potential target to inhibit pro-metastatic sys-
temic inflammation.
The last session of the meeting was focused on the ef-
fect of the microenvironment in regulation of morpho-
genesis and tumorigenesis in the mammary gland.
Charles Streuli (University of Manchester, UK) described
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his work on how the cellular microenvironment regu-
lates the circadian clock in mammary epithelial cells.
Data obtained in collaboration with Qing-Jun Meng re-
vealed several mammary epithelial genes that exhibit os-
cillating (circadian) expression. Furthermore, he showed
that the circadian clock is required for mammary stem
cell function, which is compromised during aging due to
the stroma surrounding ducts becoming stiffer [23].
Interestingly, while a stiff environment dampens rhyth-
mic gene expression in the mammary epithelia, the situ-
ation is the opposite in fibroblasts, where oscillations are
stronger in stiffer matrices [24]. Thus, epithelial and
stromal circadian clocks are inversely regulated by their
mechano-matrix environment.
Providing evidence for the importance of immunother-
apy in cancer, the talk of Xiang Zhang (Baylor College of
Medicine, Texas, USA) described his studies on the tumor
immune microenvironment. His group recently demon-
strated that Th1 CD4+ T cells have a crucial effect in
vessel normalization during tumor progression. While dis-
ruption of vessel normalization reduced T-lymphocyte in-
filtration, reciprocal deletion or inactivation of infiltrating
CD4+ T cells decreased vessel normalization, indicating a
mutually regulatory loop [25]. Despite the enormous suc-
cess of immunotherapy in some tumors, the individual pa-
tient response is highly variable due to the tremendous
inter-patient heterogeneity and the immunological hot-
ness or coldness of the tumors. Heterogeneity of the
tumor microenvironment is comparable to that of the
cancer cells themselves. It is now clear that myeloid cells,
comprising tumor-associated macrophages, neutrophils,
and myeloid-derived suppressor cells can have pleiotropic
effects in tumorigenesis and progression [26]. Using
large-scale datasets such as The Cancer Genome Atlas, he
showed that not only the composition but also phenotypes
of the myeloid cells in the tumor microenvironment vary
substantially between patients and can predict outcome,
with a large proportion of breast tumors being included in
the “cold” cluster. Breast cancer can be subtyped in a bi-
modal distribution based on the predominant myeloid
population that infiltrates the tumor, mainly tumor infil-
trating neutrophils and macrophages. This composition is
related to metastatic ability, as well as response to treat-
ments, including immunotherapy (Kim et al.,
unpublished).
The meeting in Weggis came to an end with the key-
note talk by its founding father, Mohamed Bentires-Alj
(University of Basel, Switzerland). His talk began with a
review on the tremendous success of the past 10 years
for ENBDC. The meeting that started as a small meeting
focusing on methods has progressed to a worldwide
community of mammary gland biologists and breast
cancer research. He then discussed the challenges and
opportunities of targeted therapy in the light of tumor
heterogeneity. First, he provided evidence that targeting
SHP2 could have therapeutic potential for HER2-positive
and triple-negative breast cancer patients [27, 28]. SHP2
is required for the activation of the ERK/MAPK signal-
ing pathway and controls the expression of
stemness-related genes. His data show that SHP2 is im-
portant for self-renewal of breast tumor-initiating cells
and for tumor maintenance and progression. These
studies provide new insights into signaling cascades that
regulate neoplastic breast stem cells and a rationale for
targeting SHP2 in breast cancer. He used this example
to stress the importance of the model systems that are
used, as most of the phenotypes can only be seen in 3D
culture and not in conventional 2D cultures. Finally, he
presented published data on the metastasis-promoting
activity of the chemokine CCL2 [29]. His studies call for
caution when using anti-CCL2 monotherapy as its dis-
continuation can increase metastasis formation in an
IL-6-dependent manner.
Conclusions
The tenth anniversary ENBDC meeting was, once again,
a great success. All attendees have benefitted from the
small number of participants, the methods-based talks,
and the opportunity to discuss the field with experts.
The informal talks and familiar atmosphere fostered the
interaction and encouraged everyone to discuss their un-
published work. Despite breast cancer being considered
a poorly immunogenic tumor type it cannot escape the
tremendous revolution of tumor immunotherapy. This
was the main topic of this year’s meeting, with several
talks highlighting the relevance of myeloid cells, macro-
phages, and neutrophils. The DeOme award for the best
short talk went to Sara Pensa (University of Cambridge,
UK). The 11th ENBDC meeting is set for May 16–18,
2019 and will be chaired by Zuzana Koledova (Masaryk
University in Brno, Czech Republic).
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